Drug Approval | March 17, 2022
USFDA approves Rinvoq for ulcerative colitis
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
SAATH is a ‘One AXA’ public health initiative between AXA France Vie, AXA GO Business Operations, and AXA XL
Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream
Alchemee's flagship brand Proactiv@ is an iconic product synonymous with acne care
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
The entire integration and transition of the brands is expected to be completed by March 2022
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
It is estimated that one-third of our country’s population has some form of these disorders
Subscribe To Our Newsletter & Stay Updated
